OncoMatch/Clinical Trials/NCT06393985
Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
Is NCT06393985 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Decitabine, venetoclax and blinatumomab for b-cell acute lymphoblastic leukemia.
Treatment: Decitabine, venetoclax and blinatumomab — This study aims to evaluate whether maintenance therapy with decitabine, venetoclax and blinatumomab could improve the 2-year progression free survival (PFS) of patients with philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who had recently received an allogeneic stem cell transplant and in measurable residual disease-negative remission.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR fusion (negative)
fusion gene negative
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: allogeneic hematopoietic stem cell transplant
who underwent an alloHSCT
Lab requirements
Blood counts
hematopoietic reconstitution, i.e., ANC ≥0.5 x 10^9/L, and platelets >20 x 10^9/L
Kidney function
Creatinine clearance ≥ 30 mL/min
Liver function
Total serum bilirubin ≤ 3 x upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 5 x ULN, aspartate aminotransferase (AST) ≤ 5 x ULN
Cardiac function
left ventricular ejection fraction ≥ 0.5 by echocardiography; no grade III/IV cardiovascular dysfunction (NYHA)
hematopoietic reconstitution, i.e., ANC ≥0.5 x 10^9/L, and platelets >20 x 10^9/L. Total serum bilirubin ≤ 3 x upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 5 x ULN, aspartate aminotransferase (AST) ≤ 5 x ULN. Creatinine clearance ≥ 30 mL/min. left ventricular ejection fraction < 0.5 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify